Ann: First patients recruited in COVID-19 clinical study in India, page-83

I've just been listening on the radio about the 'Rapid Antigen' Test that will be rolled out via chemists from November. They are more aimed at a person who has no symptoms yet still need to test themselves for a variety of reasons. Cost is not certain; they could be Govt subsidised but also could be upwards of $25+. Enter ResApp with it's simplistic 5 cough alternative. If we nail the asymptomatic cough then we will compete with the Rapid Antigen test. If not, then we will still have uses as a confirmation tool via coughs related to Covid, and to monitor progression of Covid through changes in the infection of the lungs demonstrated by the change in cough sound. For shareholders that would be a good result but not a great result.

SP would perhaps hang around the level it is now or even sold off a bit till demonstration of the market for the cough test by management. How fast can they get publicity out? How can they convince the TGA to fast track it? Can they even do that? They have been slow as a wet week so far with their other tricks.

However if they get the holy grail of the asymptomatic cough, all of a sudden it's a new ball game, and watch that SP take off. Even the naysayers will take notice.